BOSTON, MA — May 5, 2026 — Leads & Copy — Aura Biosciences, Inc. (Nasdaq: AURA), a clinical-stage biotechnology company, has announced the closing of its previously announced underwritten public offering, securing gross proceeds of approximately $299.4 million before deductions.
The offering involved the sale of 46,099,650 shares of common stock, including 6,508,650 shares purchased through the underwriters’ option, and pre-funded warrants to purchase up to 3,800,000 shares. The common stock was priced at $6.00 per share, while the pre-funded warrants were sold at $5.99999 per share.
Leerink Partners, TD Cowen, and Evercore ISI served as joint bookrunning managers, with LifeSci Capital also acting as a bookrunning manager and Citizens Capital Markets as a co-manager.
The offering was made under the Company’s registration statement on Form S-3 (No. 333-278253), previously filed with the SEC on March 27, 2024, and declared effective on April 5, 2024, along with a related registration statement on Form S-3MEF (File No. 333-295515) effective May 4, 2026. The final prospectus supplement was filed with the SEC on May 5, 2026, and is available on the SEC’s website.
Aura Biosciences, Inc. is focused on developing precision therapies for solid tumors, including its lead candidate, bel-sar (AU-011), currently in late-stage development for early choroidal melanoma and early-stage development for other ocular oncology indications and bladder cancer. Aura is headquartered in Boston, MA.
This announcement does not constitute an offer to sell or a solicitation to buy securities, nor will there be any sale of securities in any jurisdiction where such an offer, solicitation, or sale would be unlawful.
Source: Aura Biosciences, Inc.
